Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Thomas Flaig

Concepts (382)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Urinary Bladder Neoplasms
37
2024
197
9.490
 Why?
Prostatic Neoplasms
36
2022
927
5.980
 Why?
Kidney Neoplasms
23
2023
326
4.020
 Why?
Prostatic Neoplasms, Castration-Resistant
18
2021
40
3.940
 Why?
Antineoplastic Agents
28
2021
1893
3.590
 Why?
Antineoplastic Combined Chemotherapy Protocols
26
2022
1361
3.550
 Why?
Carcinoma, Renal Cell
18
2023
168
3.550
 Why?
Carcinoma, Transitional Cell
12
2024
54
3.370
 Why?
Androgen Antagonists
14
2020
69
2.680
 Why?
Pyrroles
7
2017
185
1.720
 Why?
Neoadjuvant Therapy
8
2024
301
1.720
 Why?
Indoles
7
2017
309
1.580
 Why?
Medical Oncology
5
2020
230
1.490
 Why?
Urologic Neoplasms
6
2023
25
1.450
 Why?
Neoplasm Metastasis
24
2021
526
1.410
 Why?
Abiraterone Acetate
9
2021
14
1.390
 Why?
Urothelium
3
2016
33
1.350
 Why?
Prednisone
14
2021
232
1.200
 Why?
Adenocarcinoma
7
2020
799
1.200
 Why?
Taxoids
7
2017
94
1.180
 Why?
Phenylurea Compounds
6
2016
83
1.160
 Why?
Antineoplastic Agents, Hormonal
8
2017
139
1.140
 Why?
Neoplasm Staging
13
2023
1178
1.140
 Why?
Mitoxantrone
5
2018
12
1.130
 Why?
Niacinamide
5
2016
65
1.080
 Why?
Prostate-Specific Antigen
11
2022
151
1.060
 Why?
Male
86
2023
55949
1.040
 Why?
Orchiectomy
4
2014
57
1.030
 Why?
Cisplatin
11
2024
263
0.990
 Why?
Humans
125
2024
115587
0.970
 Why?
Antibodies, Monoclonal, Humanized
8
2024
667
0.940
 Why?
Penile Neoplasms
1
2023
7
0.890
 Why?
Aged
52
2022
19251
0.860
 Why?
Phenylthiohydantoin
6
2021
40
0.830
 Why?
Carcinoma
2
2016
200
0.820
 Why?
Testicular Neoplasms
3
2023
95
0.810
 Why?
ErbB Receptors
6
2018
557
0.780
 Why?
Treatment Outcome
28
2023
9159
0.770
 Why?
Immunotherapy
5
2022
479
0.760
 Why?
Protein Kinase Inhibitors
6
2014
790
0.750
 Why?
Nitriles
10
2021
152
0.730
 Why?
Neoplasm Invasiveness
6
2024
445
0.720
 Why?
Aged, 80 and over
25
2021
6417
0.710
 Why?
Radiosurgery
4
2015
298
0.670
 Why?
Disease-Free Survival
12
2017
621
0.630
 Why?
Bone Neoplasms
3
2015
194
0.630
 Why?
Sulfonamides
2
2012
447
0.620
 Why?
Cystectomy
5
2024
32
0.610
 Why?
Viscera
2
2014
13
0.600
 Why?
Middle Aged
41
2021
26999
0.600
 Why?
Hematologic Diseases
2
2016
57
0.590
 Why?
Prostatectomy
5
2018
98
0.580
 Why?
Antineoplastic Agents, Immunological
2
2020
154
0.570
 Why?
Benzamides
7
2021
168
0.570
 Why?
Urinary Bladder
3
2023
165
0.560
 Why?
Erythrocytes, Abnormal
1
2016
13
0.560
 Why?
Practice Guidelines as Topic
3
2019
1405
0.560
 Why?
Prognosis
12
2023
3339
0.550
 Why?
Liver Neoplasms
3
2017
521
0.550
 Why?
Receptors, Androgen
2
2021
132
0.520
 Why?
Pancreatitis
1
2016
107
0.520
 Why?
Genomics
2
2018
645
0.510
 Why?
Silymarin
4
2013
194
0.480
 Why?
Leydig Cell Tumor
1
2014
8
0.470
 Why?
Epithelial-Mesenchymal Transition
2
2016
167
0.440
 Why?
Multicenter Studies as Topic
2
2021
249
0.430
 Why?
Chemotherapy, Adjuvant
7
2023
334
0.420
 Why?
Proto-Oncogene Proteins p21(ras)
1
2013
228
0.420
 Why?
Hypothyroidism
1
2012
65
0.410
 Why?
Gene Expression Profiling
1
2018
1536
0.410
 Why?
Administration, Intravesical
3
2022
14
0.400
 Why?
Carcinoma, Basal Cell
1
2013
68
0.400
 Why?
Sarcoma
1
2013
137
0.400
 Why?
Neoplasms, Germ Cell and Embryonal
2
2023
60
0.400
 Why?
Therapies, Investigational
1
2011
14
0.400
 Why?
Diethylstilbestrol
1
2011
8
0.390
 Why?
Angiomyolipoma
1
2011
18
0.390
 Why?
Antibodies, Monoclonal
5
2024
1265
0.380
 Why?
Receptors, Vascular Endothelial Growth Factor
2
2013
104
0.380
 Why?
Pyrazoles
2
2023
362
0.370
 Why?
Neoplastic Cells, Circulating
1
2011
59
0.370
 Why?
Leukemia, Myeloid, Acute
2
2008
538
0.370
 Why?
Disease Progression
10
2021
2418
0.370
 Why?
Lung Neoplasms
5
2017
2207
0.360
 Why?
Androstenes
4
2015
11
0.360
 Why?
Retrospective Studies
12
2024
12608
0.350
 Why?
Molecular Targeted Therapy
1
2013
348
0.350
 Why?
Receptors, Fibroblast Growth Factor
1
2010
63
0.350
 Why?
United States
10
2023
12295
0.350
 Why?
Neoplasm Proteins
1
2013
385
0.350
 Why?
Recombinant Fusion Proteins
1
2012
616
0.350
 Why?
Adult
25
2021
30718
0.350
 Why?
Kaplan-Meier Estimate
8
2016
815
0.350
 Why?
Tumor Suppressor Protein p53
1
2013
449
0.340
 Why?
Neoplasms, Multiple Primary
1
2010
52
0.340
 Why?
SEER Program
4
2023
195
0.330
 Why?
Antineoplastic Agents, Phytogenic
2
2010
181
0.330
 Why?
Neoplasm Recurrence, Local
4
2022
863
0.330
 Why?
Lymphatic Diseases
1
2009
17
0.330
 Why?
Neuroblastoma
1
2010
130
0.330
 Why?
Vascular Endothelial Growth Factors
1
2009
61
0.330
 Why?
Cystitis
1
2009
20
0.330
 Why?
Vascular Endothelial Growth Factor A
2
2019
503
0.320
 Why?
Survival Rate
9
2021
1650
0.320
 Why?
Double-Blind Method
12
2021
1660
0.310
 Why?
Androstadienes
3
2013
97
0.310
 Why?
Pneumatosis Cystoides Intestinalis
1
2008
18
0.310
 Why?
Intestinal Perforation
1
2008
38
0.310
 Why?
Female
26
2021
59913
0.310
 Why?
Precision Medicine
1
2011
344
0.310
 Why?
Pyrimidines
1
2011
376
0.310
 Why?
Clinical Trials as Topic
5
2018
941
0.310
 Why?
Deoxycytidine
3
2024
140
0.310
 Why?
Muscles
3
2024
326
0.300
 Why?
Carcinoma, Squamous Cell
1
2013
577
0.300
 Why?
Pancreatic Neoplasms
1
2014
722
0.300
 Why?
Testosterone
3
2021
337
0.300
 Why?
BCG Vaccine
2
2018
18
0.290
 Why?
Survival Analysis
6
2021
1219
0.290
 Why?
Androgen Receptor Antagonists
3
2021
30
0.280
 Why?
Combined Modality Therapy
9
2020
1127
0.280
 Why?
Nanotubes
2
2018
41
0.270
 Why?
Quinazolines
4
2019
241
0.270
 Why?
Cell Line, Tumor
7
2018
2751
0.270
 Why?
Neoplasm Grading
6
2018
244
0.270
 Why?
Carboplatin
1
2006
139
0.260
 Why?
Gold
2
2018
107
0.260
 Why?
Skin Neoplasms
1
2013
761
0.260
 Why?
Tumor Microenvironment
3
2023
431
0.260
 Why?
Lymphatic Metastasis
2
2018
276
0.260
 Why?
Gonadotropin-Releasing Hormone
2
2020
193
0.250
 Why?
Drug Resistance, Neoplasm
3
2018
638
0.250
 Why?
Biomarkers, Tumor
4
2023
1048
0.250
 Why?
Randomized Controlled Trials as Topic
3
2021
1216
0.250
 Why?
Radiotherapy, Adjuvant
2
2018
182
0.240
 Why?
Societies, Medical
2
2018
684
0.240
 Why?
Drug Synergism
3
2011
317
0.240
 Why?
Dexamethasone
1
2006
316
0.230
 Why?
Androstenols
3
2015
4
0.220
 Why?
Dose-Response Relationship, Drug
5
2013
1870
0.220
 Why?
Tosyl Compounds
4
2018
14
0.220
 Why?
Drug Administration Schedule
4
2021
724
0.220
 Why?
Gene Expression Regulation, Neoplastic
2
2021
1147
0.220
 Why?
Vitamin D
1
2006
341
0.220
 Why?
Steroid 17-alpha-Hydroxylase
2
2014
4
0.220
 Why?
Cell-Free Nucleic Acids
1
2023
27
0.210
 Why?
Anilides
4
2018
67
0.210
 Why?
Quality of Life
4
2024
2385
0.210
 Why?
Sleep Initiation and Maintenance Disorders
1
2024
116
0.200
 Why?
Patient Reported Outcome Measures
2
2024
250
0.200
 Why?
Retroperitoneal Space
1
2021
15
0.200
 Why?
Thiohydantoins
1
2021
2
0.200
 Why?
Indazoles
2
2012
58
0.200
 Why?
Tissue Extracts
2
2012
20
0.190
 Why?
Databases, Factual
2
2016
1138
0.190
 Why?
Kallikreins
2
2019
30
0.190
 Why?
Retreatment
1
2021
70
0.190
 Why?
Bone Marrow Transplantation
1
2002
239
0.190
 Why?
Time Factors
5
2020
6165
0.180
 Why?
Tomography, X-Ray Computed
4
2014
2392
0.180
 Why?
Genetic Heterogeneity
1
2020
51
0.180
 Why?
Phosphatidylcholines
2
2013
134
0.170
 Why?
Yttrium
1
2018
5
0.160
 Why?
In Situ Hybridization, Fluorescence
2
2011
310
0.160
 Why?
Angiogenesis Inhibitors
2
2021
216
0.160
 Why?
Cell Adhesion Molecules
1
2020
168
0.160
 Why?
Fluorides
1
2018
45
0.160
 Why?
Euterpe
1
2018
5
0.160
 Why?
Central Nervous System
1
2020
239
0.160
 Why?
Organ Sparing Treatments
1
2018
31
0.160
 Why?
Piperidines
2
2010
163
0.160
 Why?
Costimulatory and Inhibitory T-Cell Receptors
1
2018
7
0.160
 Why?
Lymph Node Excision
2
2021
141
0.150
 Why?
Odds Ratio
1
2021
962
0.150
 Why?
Congresses as Topic
2
2012
204
0.150
 Why?
Tumor Escape
1
2018
35
0.150
 Why?
Antioxidants
2
2013
533
0.150
 Why?
History, 21st Century
2
2015
162
0.150
 Why?
Apoptosis
1
2007
2377
0.150
 Why?
Cancer Vaccines
1
2019
137
0.150
 Why?
Genome
1
2020
271
0.150
 Why?
Neoplasm, Residual
2
2021
105
0.150
 Why?
Microscopy, Fluorescence
3
2018
402
0.150
 Why?
Proton Therapy
1
2017
10
0.140
 Why?
Blotting, Western
2
2010
1153
0.140
 Why?
Goserelin
3
2018
8
0.140
 Why?
Practice Patterns, Physicians'
2
2016
1180
0.140
 Why?
Erythrocyte Indices
1
2016
27
0.140
 Why?
Plant Extracts
1
2018
153
0.140
 Why?
Biopsy
3
2018
1056
0.140
 Why?
Aftercare
1
2018
187
0.140
 Why?
Dyslipidemias
1
2018
154
0.140
 Why?
Fatal Outcome
2
2008
286
0.140
 Why?
Watchful Waiting
1
2016
57
0.140
 Why?
Oligopeptides
1
2018
248
0.130
 Why?
Adverse Drug Reaction Reporting Systems
1
2016
69
0.130
 Why?
United States Food and Drug Administration
1
2016
173
0.130
 Why?
High-Throughput Nucleotide Sequencing
1
2018
443
0.130
 Why?
Prostate
2
2021
157
0.130
 Why?
Disease Management
1
2019
563
0.120
 Why?
Nanoparticles
1
2018
316
0.120
 Why?
Soft Tissue Neoplasms
1
2015
90
0.120
 Why?
Patient Selection
1
2018
654
0.120
 Why?
Radiation Tolerance
1
2015
92
0.120
 Why?
Insurance, Health
1
2016
246
0.120
 Why?
Cytochrome P-450 Enzyme Inhibitors
1
2014
4
0.120
 Why?
Ablation Techniques
1
2014
29
0.120
 Why?
Mitotic Index
1
2014
26
0.120
 Why?
Neoplasms, Hormone-Dependent
1
2014
38
0.110
 Why?
Hyperthermia, Induced
1
2014
65
0.110
 Why?
Neoplasms, Complex and Mixed
1
2013
7
0.110
 Why?
Carcinoma, Medullary
1
2013
13
0.110
 Why?
Magnetic Resonance Imaging
3
2021
3069
0.110
 Why?
beta-Galactosidase
1
2013
63
0.110
 Why?
Receptor, ErbB-2
1
2016
302
0.110
 Why?
Breeding
1
2013
55
0.110
 Why?
Glucocorticoids
1
2018
552
0.110
 Why?
Geriatrics
1
2014
69
0.110
 Why?
Sirolimus
2
2014
192
0.110
 Why?
Reproducibility of Results
2
2013
2800
0.110
 Why?
Interleukin-2
1
2014
417
0.110
 Why?
Brain Neoplasms
1
2021
980
0.110
 Why?
Staining and Labeling
1
2013
139
0.110
 Why?
Hyperplasia
1
2013
166
0.110
 Why?
Keratins
1
2013
176
0.110
 Why?
Urogenital Neoplasms
1
2012
4
0.110
 Why?
Tumor Stem Cell Assay
1
2012
33
0.110
 Why?
Cell Proliferation
2
2012
2194
0.110
 Why?
Organ Specificity
1
2013
273
0.110
 Why?
Nephrectomy
2
2013
150
0.110
 Why?
Population Surveillance
1
2015
395
0.110
 Why?
Adenoviridae
1
2013
186
0.110
 Why?
Integrases
1
2013
117
0.110
 Why?
Fluorescent Antibody Technique
1
2013
398
0.100
 Why?
Celecoxib
1
2012
38
0.100
 Why?
Thyroid Hormones
1
2012
53
0.100
 Why?
Thyroid Gland
1
2012
83
0.100
 Why?
Quinolines
1
2013
129
0.100
 Why?
RNA, Untranslated
1
2013
113
0.100
 Why?
Bone Diseases
1
2012
58
0.100
 Why?
Cross-Over Studies
3
2021
434
0.100
 Why?
Reoperation
1
2014
525
0.100
 Why?
Carcinoma, Hepatocellular
1
2013
224
0.100
 Why?
Imidazoles
1
2012
217
0.100
 Why?
Denosumab
1
2010
7
0.090
 Why?
PubMed
1
2010
11
0.090
 Why?
RANK Ligand
1
2010
26
0.090
 Why?
Benzenesulfonates
1
2010
21
0.090
 Why?
Animals
5
2016
32102
0.090
 Why?
Neoplasms
2
2022
2118
0.090
 Why?
Erlotinib Hydrochloride
1
2010
65
0.090
 Why?
Vimentin
1
2010
57
0.090
 Why?
Insulin-Like Growth Factor Binding Protein 3
1
2010
38
0.090
 Why?
Cell Separation
1
2011
293
0.090
 Why?
Xenograft Model Antitumor Assays
1
2012
704
0.090
 Why?
Hypertension
1
2018
1064
0.090
 Why?
Mesoderm
1
2010
138
0.090
 Why?
Tumor Cells, Cultured
1
2011
850
0.080
 Why?
Cadherins
1
2010
175
0.080
 Why?
Cardiovascular Diseases
2
2018
1724
0.080
 Why?
Carcinoma, Papillary
1
2009
73
0.080
 Why?
Age Factors
1
2016
2907
0.080
 Why?
Nephrolithiasis
1
2009
10
0.080
 Why?
Metaplasia
1
2009
54
0.080
 Why?
Gynecomastia
1
2008
4
0.080
 Why?
Chromatography, Liquid
1
2010
347
0.080
 Why?
Risk Factors
5
2018
8697
0.080
 Why?
Risk
1
2011
819
0.080
 Why?
Genotype
1
2013
1786
0.080
 Why?
Mice, Transgenic
1
2013
1970
0.080
 Why?
Drug Therapy, Combination
1
2011
962
0.080
 Why?
Tandem Mass Spectrometry
1
2010
414
0.080
 Why?
Proportional Hazards Models
3
2016
1087
0.080
 Why?
Southwestern United States
1
2008
92
0.080
 Why?
Insulin-Like Growth Factor I
1
2010
281
0.080
 Why?
Liver Failure, Acute
1
2008
60
0.080
 Why?
Hormone Replacement Therapy
1
2008
77
0.080
 Why?
Mediastinal Diseases
1
2007
10
0.080
 Why?
Carcinoid Tumor
1
2007
25
0.070
 Why?
Pyridines
1
2010
425
0.070
 Why?
Mice
2
2013
15052
0.070
 Why?
Glucuronides
1
2006
13
0.070
 Why?
Neoplasms, Second Primary
1
2008
91
0.070
 Why?
Spectrophotometry, Ultraviolet
1
2006
75
0.070
 Why?
Medical History Taking
1
2007
114
0.070
 Why?
Excipients
1
2006
49
0.070
 Why?
Liver Function Tests
1
2006
105
0.070
 Why?
Chemistry, Pharmaceutical
1
2006
99
0.070
 Why?
Syndrome
1
2007
339
0.070
 Why?
Antibiotics, Antineoplastic
1
2006
114
0.070
 Why?
Spectrometry, Mass, Electrospray Ionization
1
2006
165
0.070
 Why?
Pedigree
1
2007
467
0.070
 Why?
Sarcoidosis
1
2007
134
0.070
 Why?
Everolimus
2
2017
63
0.070
 Why?
Radiography
1
2008
826
0.060
 Why?
Signal Transduction
2
2016
4541
0.060
 Why?
Doxorubicin
1
2006
290
0.060
 Why?
Forecasting
1
2007
333
0.060
 Why?
Metabolic Syndrome
1
2008
324
0.060
 Why?
Biomarkers
2
2023
3466
0.060
 Why?
Epithelial Cells
1
2010
961
0.060
 Why?
DNA Damage
1
2007
357
0.060
 Why?
Gastrointestinal Diseases
1
2006
184
0.060
 Why?
Diagnosis, Differential
1
2009
1357
0.060
 Why?
Melanoma
1
2011
651
0.060
 Why?
Referral and Consultation
1
2009
646
0.060
 Why?
Radiotherapy
2
2015
177
0.060
 Why?
Carcinoma, Non-Small-Cell Lung
1
2012
963
0.060
 Why?
Young Adult
4
2021
10470
0.060
 Why?
Disease Models, Animal
1
2012
3580
0.050
 Why?
Follow-Up Studies
2
2015
4440
0.050
 Why?
Immunohistochemistry
2
2020
1642
0.050
 Why?
Maximum Tolerated Dose
2
2013
182
0.050
 Why?
Immune System Diseases
1
2002
35
0.050
 Why?
Steroid Synthesis Inhibitors
1
2021
1
0.050
 Why?
Policy
1
2022
140
0.050
 Why?
Clinical Trials, Phase III as Topic
1
2021
84
0.050
 Why?
Proteomics
1
2007
859
0.050
 Why?
Prednisolone
1
2021
77
0.050
 Why?
Mass Screening
1
2008
1024
0.050
 Why?
Metabolic Diseases
1
2002
99
0.050
 Why?
Tumor Burden
1
2021
261
0.050
 Why?
Bevacizumab
1
2021
118
0.050
 Why?
Phosphatidylinositol 3-Kinases
1
2022
332
0.050
 Why?
Asymptomatic Diseases
1
2021
77
0.050
 Why?
Proto-Oncogene Proteins c-akt
1
2022
400
0.050
 Why?
TOR Serine-Threonine Kinases
1
2022
362
0.040
 Why?
Neovascularization, Pathologic
1
2021
283
0.040
 Why?
Ytterbium
1
2018
2
0.040
 Why?
Erbium
1
2018
5
0.040
 Why?
HLA-A2 Antigen
1
2019
37
0.040
 Why?
Hospitals
1
2023
585
0.040
 Why?
Estrogen Receptor alpha
1
2020
120
0.040
 Why?
Risk Assessment
1
2008
2987
0.040
 Why?
Fruit and Vegetable Juices
1
2018
11
0.040
 Why?
DNA Methylation
1
2023
498
0.040
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2021
242
0.040
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
1
2019
140
0.040
 Why?
Luminescent Measurements
1
2018
74
0.040
 Why?
Lasers
1
2018
121
0.040
 Why?
Pain
1
2024
712
0.040
 Why?
Laparoscopy
1
2021
400
0.040
 Why?
National Cancer Institute (U.S.)
1
2017
40
0.040
 Why?
Antibodies
1
2018
374
0.030
 Why?
Risk Reduction Behavior
1
2018
201
0.030
 Why?
DNA
1
2023
1356
0.030
 Why?
Abdominal Neoplasms
1
2015
26
0.030
 Why?
Molecular Diagnostic Techniques
1
2016
91
0.030
 Why?
Thoracic Neoplasms
1
2015
33
0.030
 Why?
Placebos
1
2015
198
0.030
 Why?
Radiotherapy Planning, Computer-Assisted
1
2015
118
0.030
 Why?
Nanoconjugates
1
2014
1
0.030
 Why?
Administration, Oral
1
2017
734
0.030
 Why?
Spectrophotometry, Atomic
1
2014
13
0.030
 Why?
Antihypertensive Agents
1
2018
432
0.030
 Why?
Platelet Aggregation Inhibitors
1
2018
399
0.030
 Why?
Lipids
1
2018
588
0.030
 Why?
Radiotherapy, Intensity-Modulated
1
2015
123
0.030
 Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
2018
373
0.030
 Why?
Smoking Cessation
1
2018
377
0.030
 Why?
Benchmarking
1
2015
163
0.030
 Why?
Accidental Falls
1
2015
151
0.030
 Why?
Cell Death
1
2014
326
0.030
 Why?
Blood Pressure
1
2018
1537
0.020
 Why?
Hydroxamic Acids
1
2012
80
0.020
 Why?
Prospective Studies
1
2023
6264
0.020
 Why?
Health Policy
1
2014
334
0.020
 Why?
Dose-Response Relationship, Radiation
1
2011
130
0.020
 Why?
Histone Deacetylase Inhibitors
1
2012
199
0.020
 Why?
Androgens
1
2011
165
0.020
 Why?
Seizures
1
2012
344
0.020
 Why?
Polyethylene Glycols
1
2014
576
0.020
 Why?
Fatigue
1
2011
296
0.020
 Why?
Sex Factors
1
2014
1736
0.020
 Why?
Multivariate Analysis
1
2012
1440
0.020
 Why?
Positron-Emission Tomography
1
2009
284
0.020
 Why?
Radionuclide Imaging
1
2007
121
0.020
 Why?
Cell Membrane Permeability
1
2006
83
0.020
 Why?
Head and Neck Neoplasms
1
2008
425
0.010
 Why?
Cell Survival
1
2006
1024
0.010
 Why?
Ultrasonography
1
2006
641
0.010
 Why?
Incidence
1
2008
2335
0.010
 Why?
Flaig's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (382) concept(s)
_
Co-Authors Expand Description
See all (46) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)